Phenotypic and genotypic characterization of Extended Spectrum β-lactamases producing Proteus mirabilis isolates.
Lamiaa A. Salama, Hazem Hamed Saleh, Shaymaa Hassan Abdel-Rhman, Rasha Fathy Barwa, Ramadan Hassan
Abstract
Open-access reader
Lamiaa A. Salama, Hazem Hamed Saleh, Shaymaa Hassan Abdel-Rhman, Rasha Fathy Barwa, Ramadan Hassan
Abstract
Open-access reader
Background: The Extended spectrum β-lactamases (ESBLs) production is one of the most essential mechanism of drug resistance in Proteus mirabilis (P. mirabilis). Objective: Phenotypic and genotypic detection of extended spectrum β -lactamases production in P. mirabilis and its antimicrobial resistance among clinical isolates. Methods: A total of Sixty P. mirabilis clinical isolates were tested for Extended spectrum β lactamase production by modified double disc synergy test (MDDST). Polymerase chain reaction (PCR) was done to detect Extended spectrum β-lactamases genes in the clinical isolates. Antimicrobial susceptibility testing was done by means of Kirby Bauer disc diffusion method. Results: Out of the 60 P. mirabilis clinical isolates, 17 isolates (28.33%) were ESBL producers by phenotypic test. Genotypically; ESBLs genes were detected and the most prevalent ESBL resistance gene was TEM (91.7%) followed by SHV (75%), CTX-2-59 (56.7%) and CtxM-15 (51.7%). Moderate level of resistance to ofloxacin, ciprofloxacin, amoxicillin/ clavulanic acid, cefotaxime and ceftazidime (60.0%, 58.3%, 45.0%, 41.7% and 40.0% respectively) was recorded. In addition, 73.33% of isolates were classified as multidrug resistant (MDR). Conclusion: Monitoring of Extended spectrum β-lactamase producing P. mirabilis is very important because of its high prevalence among urinary tract infections. Also; increasing awareness for clinicians and enhancing laboratories
OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Background: The Extended spectrum β-lactamases (ESBLs) production is one of the most essential mechanism of drug resistance in Proteus mirabilis (P. mirabilis). Objective: Phenotypic and genotypic detection of extended spectrum β -lactamases production in P. mirabilis and its antimicrobial resistance among clinical isolates. Methods: A total of Sixty P. mirabilis clinical isolates were tested for Extended spectrum β lactamase production by modified double disc synergy test (MDDST). Polymerase chain reaction (PCR) was done to detect Extended spectrum β-lactamases genes in the clinical isolates. Antimicrobial susceptibility testing was done by means of Kirby Bauer disc diffusion method. Results: Out of the 60 P. mirabilis clinical isolates, 17 isolates (28.33%) were ESBL producers by phenotypic test. Genotypically; ESBLs genes were detected and the most prevalent ESBL resistance gene was TEM (91.7%) followed by SHV (75%), CTX-2-59 (56.7%) and CtxM-15 (51.7%). Moderate level of resistance to ofloxacin, ciprofloxacin, amoxicillin/ clavulanic acid, cefotaxime and ceftazidime (60.0%, 58.3%, 45.0%, 41.7% and 40.0% respectively) was recorded. In addition, 73.33% of isolates were classified as multidrug resistant (MDR). Conclusion: Monitoring of Extended spectrum β-lactamase producing P. mirabilis is very important because of its high prevalence among urinary tract infections. Also; increasing awareness for clinicians and enhancing laboratories
Key concepts: Proteus mirabilis, Ceftazidime, Microbiology, Cefotaxime, Clavulanic acid, Biology, Genotype, Multiple drug resistance